, 169:67 | Cite as

Genotyping and Antifungal Drug Susceptibility of the Pathogenic Yeast Trichosporon asahii Isolated from Thai Patients

  • Nanthawan Mekha
  • Takashi SugitaEmail author
  • Reiko Ikeda
  • Akemi Nishikawa
  • Rinrapas Autthateinchai
  • Natteewan Poonwan
  • Pathom Sawanpanyalert


Trichosporonosis due to Trichosporon asahii is a life-threatening infection with a very poor prognosis. We analyzed the genotype of intergenic transcribed spacer (IGS) region 1 of the rRNA gene and determined the drug susceptibility of 101 T. asahii isolates obtained from Thai patients to collect basic information on trichosporonosis in Thailand. Of the five genotypes in the IGS region identified in this study, types 1 and 3 were predominant in Thailand. The distribution in Thailand differs from that in other countries, suggesting that there is a geographic substructure among T. asahii clinical isolates. Voriconazole appeared to be the most active drug.


Trichosporon asahii Genotype Intergenic spacer region Antifungal drug susceptibility 



This study was supported in part by research grants from the Asian and African Science Platform Program of the Japan Society for the Promotion of Science, and a Health Science Research Grant for “Research on Emerging and Re-emerging Infectious Diseases” from the Ministry of Health, Labor, and Welfare of Japan (TS).


  1. 1.
    Guého E, Improvisi L, de Hoog GS, Dupont B. Trichosporon on humans: a practical account. Mycoses. 1994;37:3–10.CrossRefPubMedGoogle Scholar
  2. 2.
    Sugita T, Ikeda R, Nishikawa A. Analysis of Trichosporon isolates obtained from the houses of patients with summer-type hypersensitivity pneumonitis. J Clin Microbiol. 2004;42:5467–71.CrossRefPubMedGoogle Scholar
  3. 3.
    Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect Suppl 1. 2004; 48–66.Google Scholar
  4. 4.
    Girmenia C, Pagano L, Martino B, D’Antonio D, Fanci R, Specchia G, et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol. 2005;43:1818–28.CrossRefPubMedGoogle Scholar
  5. 5.
    Falk R, Wolf DG, Shapiro M, Polacheck I. Multidrug-resistant Trichosporon asahii isolates are susceptible to voriconazole. J Clin Microbiol. 2003;41:911.CrossRefPubMedGoogle Scholar
  6. 6.
    Wolf DG, Falk R, Hacham M, Theelen B, Boekhout T, Scorzetti G, et al. Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units. J Clin Microbiol. 2001;39:4420–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Kanngurn S, Parichatikanond P, Pootong V, Vichyanond P. Chronic Granulomatous Disease with Disseminated Trichosporonosis: A Case Report. Siriraj J. 2001;53:542–8.Google Scholar
  8. 8.
    Anunnatsiri S, Chetchotisakd P, Mootsikapun P. Fungemia in non-HIV-infected patients: a five-year review. Int J Infect Dis. 2009;13:90–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Makimura K, Murayama SY, Yamaguchi H. Detection of a wide range of medically important fungi by the polymerase chain reaction. J Med Microbiol. 1994;40:358–64.CrossRefPubMedGoogle Scholar
  10. 10.
    Sugita T, Nakajima M, Ikeda R, Matsushima T, Shinoda T. Sequence analysis of the ribosomal DNA intergenic spacer 1 regions of Trichosporon species. J Clin Microbiol. 2002;40:1826–30.CrossRefPubMedGoogle Scholar
  11. 11.
    National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. National Committee for Clinical Laboratory Standards, Wayne, PA, 2002.Google Scholar
  12. 12.
    Kalkanci A, Sugita T, Arikan S, Yucesoy M, Ener B, Otag F, Kiraz N, Kustimur S, Sancak B, Evci C, Emektas G. Molecular identification, genotyping, and drug susceptibility of the basidiomycetous yeast pathogen Trichosporon isolated from Turkish patients. Medical Mycol. in press.Google Scholar
  13. 13.
    Ando M, Suga M, Nishiura Y, Miyajima M. Summer-type hypersensitivity pneumonitis. Intern Med. 1995;34:707–12.CrossRefPubMedGoogle Scholar
  14. 14.
    Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Bijie H, Dzierzanowska D, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2009;47:117–23.CrossRefPubMedGoogle Scholar
  15. 15.
    Rodriguez-Tudela JL, Diaz-Guerra TM, Mellado E, Cano V, Tapia C, Perkins A, et al. Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob Agents Chemother. 2005;49:4026–34.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Nanthawan Mekha
    • 1
    • 2
  • Takashi Sugita
    • 2
    Email author
  • Reiko Ikeda
    • 2
  • Akemi Nishikawa
    • 3
  • Rinrapas Autthateinchai
    • 1
  • Natteewan Poonwan
    • 1
  • Pathom Sawanpanyalert
    • 4
  1. 1.Department of Medical Sciences, Mycology LaboratoryNational Institute of HealthNonthaburiThailand
  2. 2.Department of MicrobiologyMeiji Pharmaceutical UniversityTokyoJapan
  3. 3.Department of ImmunobiologyMeiji Pharmaceutical UniversityKiyose, TokyoJapan
  4. 4.Department of Medical SciencesNational Institute of HealthNonthaburiThailand

Personalised recommendations